CMAI
REGN icon

Capital Management Associates Inc’s Regeneron Pharmaceuticals REGN Stock Holding History

Capital Management Associates Inc’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-279
Closed -$216K – 160
2026
Q1 		$216K Buy
+279
New +$214K 0.05% 144

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WCM
Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.87B AUM 24.22% 1-Year Est. Return

Capital Management Associates Inc's REGN Position: Q2 2026 in Review

Capital Management Associates Inc sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 279 shares — an estimated $216K sold.

Capital Management Associates Inc first reported a position in REGN in Q1 2026 and held it in 1 quarter. The position peaked at $216K in Q1 2026. 315 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Capital Management Associates Inc reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Capital Management Associates Inc sold 279 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $216K.
  • Capital Management Associates Inc first reported a position in Regeneron Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Capital Management Associates Inc's Regeneron Pharmaceuticals position peaked at $216K in Q1 2026.
  • 315 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Capital Management Associates Inc's 13F filing for Q2 2026, filed 22 Jul 2026.